靶向多巴胺D3受体治疗精神分裂症的研究  

Study of Targeting Dopamine D3 Receptor in the Treatment of Schizophrenia

作　　者：顾钧 谢小虎[1] 符丹 李龙辉 陈为升[1] 刘惠芬[1] 周文华[1] GU Jun;XIE Xiaohu;FU Dan;LI Longhui;CHEN Weisheng;LIU Huifen;ZHOU Wenhua(Department of Psychiatry,Affiliated Kangning Hospital of Ningbo University,Ningbo Kangning Hospital/Zhejiang Province Key Laboratory of Addiction Research,Ningbo 315201,Zhejiang,China)

机构地区：[1]宁波大学附属康宁医院精神科/宁波市康宁医院精神科/浙江省戒毒研究重点实验室,浙江宁波315201

出　　处：《中国药物滥用防治杂志》2024年第6期979-983,共5页Chinese Journal of Drug Abuse Prevention and Treatment

基　　金：国家重点研发计划(编号:2022YFC3300905)。

摘　　要：精神分裂症的发生与脑内多巴胺功能失调有关。近年来多巴胺D3受体在精神分裂症中的作用引起临床广泛关注,临床前和临床研究显示,一些多巴胺选择性D3受体拮抗剂和部分激动剂对精神分裂症阴性症状和认知障碍具有明显的治疗效果。与多巴胺D2受体相比,多巴胺D3受体在脑内分布相对局限,靶向D3受体的药物在应用时较少引起如锥体外系反应等副作用。因此,D3受体有望成为治疗神经精神疾病新的靶点,这也预示着将来这些复杂的精神疾病可能会得到更有效的治疗。本文对多巴胺D3受体进行概述,以及精神分裂症多巴胺假说背景下D3受体功能失调的机制做一综述,以期为临床治疗提供参考。The occurrence of schizophrenia is related to the dysfunction of dopamine in the brain.In recent years,the role of dopamine D3 receptor in schizophrenia has attracted extensive clinical attention.Preclinical and clinical studies have shown that some dopamine selective D3 receptor antagonists and some agonists have obvious therapeutic effects on negative symptoms and cognitive impairment of schizophrenia.Compared with dopamine D2 receptor,the distribution of dopamine D3 receptor in the brain is relatively limited,and drugs targeting D3 receptor are less likely to cause side effects such as extrapyramidal reactions.Therefore,D3 receptor is expected to become a new target for the treatment of neuropsychiatric diseases,which also indicates that these complex mental diseases may be treated more effectively in the future.This article summarizes the dopamine D3 receptor and the mechanism of D3 receptor dysfunction in the context of the dopamine hypothesis of schizophrenia,in order to provide a reference forclinical treatment.

关 键 词：多巴胺D3受体 选择性拮抗剂 部分激动剂 精神分裂症 

分 类 号：R749.3[医药卫生—神经病学与精神病学]